| 000 | 01256 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250513191316.0 | ||
| 264 | 0 | _c19991026 | |
| 008 | 199910s 0 0 eng d | ||
| 022 | _a0163-7258 | ||
| 024 | 7 |
_a10.1016/s0163-7258(98)00051-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNoble, M E | |
| 245 | 0 | 0 |
_aChemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. _h[electronic resource] |
| 260 |
_bPharmacology & therapeutics _c |
||
| 300 |
_a269-78 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xmetabolism |
| 650 | 0 | 4 | _aBinding Sites |
| 650 | 0 | 4 | _aCrystallography, X-Ray |
| 650 | 0 | 4 |
_aCyclins _xphysiology |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aPhosphotransferases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 700 | 1 | _aEndicott, J A | |
| 773 | 0 |
_tPharmacology & therapeutics _gvol. 82 _gno. 2-3 _gp. 269-78 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0163-7258(98)00051-5 _zAvailable from publisher's website |
| 999 |
_c10411881 _d10411881 |
||